Subtype
Skin Basal Cell Carcinoma
CI-CAN-00003940BCCExplore in graph →
17 active trials1 approved drugs
Loading cancer entity…
Subtype
CI-CAN-00003940BCCExplore in graph →
Clinical trials
83 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (4)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03573401 | Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). | active not recruiting | Phase 3 | 187 | Biofrontera Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jan 14, 2026source: clinicaltrials